BioSpace News Archive

The FDA plans to convene an advisory committee meeting to discuss the safety profile and efficacy of Eli Lilly’s Alzheimer’s candidate, the company announced Friday.

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced positive topline results from its open-label Phase 2 carcinoid syndrome study of paltusotine, an oral, once-daily investigational compound being developed for the treatment of acromegaly and carcinoid syndrome.

Neurona Therapeutics today announced that Cory R. Nicholas, Ph.D., Neurona’s chief executive officer, will present a corporate update on Tuesday, March 19 at 5:00 pm ET and host one-on-one meetings during the Stifel 2024 Virtual CNS Days taking place on March 19-20, 2024.

MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT) today announced its fourth quarter and full year ended December 31, 2023 financial results and reiterated its 2024 guidance.

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its fourth quarter and full-year ended December 31, 2023.

Cryoport, Inc. (NASDAQ: CYRX) (“Cryoport”), a global leader in supply chain solutions for cell & gene therapies, today announced financial results for the fourth quarter (Q4) and year (FY) ended December 31, 2023.

Precigen, Inc. (Nasdaq: PGEN) today announced that Cantor Fitzgerald will be hosting a virtual fireside chat with Precigen on Monday, March 25, 2024 at 1:00 PM ET to discuss the investigational PRGN-2012 AdenoVerse™ immunotherapy for the treatment of recurrent respiratory papillomatosis (RRP).

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported full year 2023 financial results.

Panbela Therapeutics, Inc. (Nasdaq: PBLA), (“Panbela”) today announced that it will host a conference call on March 26, 2024, at 4:30 PM Eastern Time to discuss results for its fourth quarter and year ended December 31, 2023.

Ardelyx, Inc. announced that on March 9, 2024, the compensation committee of the company’s board of directors granted nine new non-executive employees options to purchase an aggregate of 207,038 shares of the company’s common stock, and granted twelve new non-executive employees an aggregate of 157,450 Restricted Stock Units.